Novo Nordisk opens new pilot plant in Hillerod, Denmark
A new pilot plant for the development and production of new biopharmaceuticals based on proteins cultured in mammalian cells, has been opened by Novo Nordisk.
A new pilot plant for the development and production of new biopharmaceuticals based on proteins cultured in mammalian cells, has been opened by Novo Nordisk.
The new pilot plant is an extension of Novo Nordisk's existing production facility in Hillerod and contains development laboratories and production facilities. With a total floor space of 3,500 m2, the plant represents an investment of DK 350m (Euro 47m).
"This new pilot plant underlines Novo Nordisk's strong commitment to biopharmaceuticals, both within existing areas such as haemostasis, and new areas such as inflammation and cancer. It will significantly increase our capacity for producing investigational compounds for clinical trials," said Mads Krogsgaard Thomsen, chief science officer and executive vice president of Novo Nordisk.
Some of the first investigational compounds to be produced by the new facility are antibodies against cancer.
Today Novo Nordisk's commercial production of biopharmaceuticals is based on three different types of cells: yeast, E coli and mammalian cells.